MicroRNA diagnostics gain momentum

In December 2008, Israeli company Rosetta Genomics (Nasdaq: ROSG) announced that its first three MicroRNA (miRNA)-based cancer diagnostics are now commercially available (miRNAs are thought to inhibit the translation of messenger RNA - mRNA - into associated protein, and the presence of certain patt...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

New insights about human immune response to COVID-19 have implications for vaccine design against new variants

News Commentary | May 07, 2021

Multiple new and emerging COVID‑19 variants with higher transmission rates have thrown into question the continued efficacy of existing vaccines across these newer strains. Previous research has focused on the receptor‑binding domain (RBD) given its importance in attaching to and infecting human ... To read more, click here.

NHS launches world's largest liquid biopsy trial, which could potentially detect 50 types of cancer

News Commentary | September 17, 2021

NHS will use GRAIL's Galleri test in this study, which aims to recruit 140,000 volunteers in eight areas of England. Besides being touted as the world's first and largest clinical trial of its kind, the more important significance of this study is that it is being spearheaded by one of the largest ... Not part of subscription

23andMe expands portfolio of approved cancer screenings with latest FDA approval

News Commentary | January 13, 2022

The U.S. FDA has given 23andMe approval to expand its genetic health risk report by screening for a G84E mutation in the HOXB13 gene. This mutation has been linked to an increase in prostate cancer. A recent study showed that males with a G84E gene mutation were 66% more likely to have prostate ... To read more, click here.